Related Experiment Video
Updated: Aug 6, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
SIRT7 orchestrates melanoma progression by simultaneously promoting cell survival and immune evasion via UPR
Xiuli Yi1, Huina Wang1, Yuqi Yang1
1Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No 127 of West Changle Road, Xi'an, Shaanxi, 710032, China.
Abstract:
Melanoma is the most lethal type of skin cancer, originating from the malignant transformation of melanocyte. While the development of targeted therapy and immunotherapy has gained revolutionary advances in potentiating the therapeutic effect, the prognosis of patients with melanoma is still suboptimal. During tumor progression, melanoma frequently encounters stress from both endogenous and exogenous sources in tumor microenvironment. SIRT7 is a nuclear-localized deacetylase of which the activity is highly dependent on intracellular nicotinamide adenine dinucleotide (NAD+), with versatile biological functions in maintaining cell homeostasis. Nevertheless, whether SIRT7 regulates tumor cell biology and tumor immunology in melanoma under stressful tumor microenvironment remains elusive. Herein, we reported that SIRT7 orchestrates melanoma progression by simultaneously promoting tumor cell survival and immune evasion via the activation of unfolded protein response. We first identified that SIRT7 expression was the most significantly increased one in sirtuins family upon stress. Then, we proved that the deficiency of SIRT7 potentiated tumor cell death under stress in vitro and suppressed melanoma growth in vivo. Mechanistically, SIRT7 selectively activated the IRE1α-XBP1 axis to potentiate the pro-survival ERK signal pathway and the secretion of tumor-promoting cytokines. SIRT7 directly de-acetylated SMAD4 to antagonize the TGF-β-SMAD4 signal, which relieved the transcriptional repression on IRE1α and induced the activation of the IRE1α-XBP1 axis. Moreover, SIRT7 up-regulation eradicated anti-tumor immunity by promoting PD-L1 expression via the IRE1α-XBP1 axis. Additionally, the synergized therapeutic effect of SIRT7 suppression and anti-PD-1 immune checkpoint blockade was also investigated. Taken together, SIRT7 can be employed as a promising target to restrain tumor growth and increase the effect of melanoma immunotherapy.
Insights
SIRT7 promotes melanoma growth and immune evasion by activating the unfolded protein response. Suppressing SIRT7 may enhance immunotherapy effectiveness against this lethal skin cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Melanoma remains a lethal skin cancer with suboptimal patient prognosis despite advances in therapy.
- The tumor microenvironment presents significant stress to melanoma cells.
- SIRT7, a NAD+-dependent deacetylase, maintains cell homeostasis, but its role in melanoma under stress is unclear.
Purpose of the Study:
- To investigate the role of SIRT7 in melanoma progression and immune evasion under stressful conditions.
- To elucidate the underlying molecular mechanisms by which SIRT7 influences melanoma cell survival and the tumor microenvironment.
Main Methods:
- Assessed SIRT7 expression levels in sirtuins family under stress.
- Utilized in vitro and in vivo models to evaluate the effects of SIRT7 deficiency on melanoma.
- Investigated SIRT7's impact on the IRE1α-XBP1 axis, ERK signaling, and cytokine secretion.
- Examined SIRT7's regulation of SMAD4 and TGF-β signaling.
- Analyzed SIRT7's role in PD-L1 expression and anti-tumor immunity.
- Evaluated combination therapy of SIRT7 suppression and anti-PD-1 blockade.
Main Results:
- SIRT7 expression significantly increased under stress and was the highest among sirtuins.
- SIRT7 deficiency led to increased tumor cell death under stress and suppressed melanoma growth in vivo.
- SIRT7 activated the IRE1α-XBP1 pathway, enhancing pro-survival ERK signaling and tumor-promoting cytokines.
- SIRT7 de-acetylated SMAD4, antagonizing TGF-β signaling and promoting IRE1α-XBP1 activation.
- SIRT7 upregulation promoted PD-L1 expression, contributing to immune evasion.
- Combined SIRT7 suppression and anti-PD-1 blockade showed synergistic therapeutic effects.
Conclusions:
- SIRT7 drives melanoma progression by promoting cell survival and immune evasion through the unfolded protein response.
- SIRT7 directly impacts key signaling pathways, including IRE1α-XBP1, ERK, and TGF-β.
- SIRT7 inhibition represents a potential therapeutic strategy to overcome resistance and enhance melanoma immunotherapy.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
PI3K/mTOR/AKT Signaling Pathway
MicroRNAs
Regulation of the Unfolded Protein Response

